Imaging hypoxia and angiogenesis in tumors

被引：113

作者：

Rajendran, JG

Krohn, KA

机构：

[1] Univ Washington, Dept Radiol, Div Nucl Med, Seattle, WA 98195 USA

[2] Univ Washington, Dept Radiat Oncol, Seattle, WA USA

来源：

RADIOLOGIC CLINICS OF NORTH AMERICA | 2005年 / 43卷 / 01期

关键词：

D O I：

10.1016/j.rcl.2004.08.004

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

There is a clear need in cancer treatment for a noninvasive imaging assay that evaluates the oxygenation status and heterogeneity of hypoxia and angiogenesis in individual patients. Such an assay could be used to select alternative treatments and to monitor the effects of treatment. Of the several methods available, each imaging procedure has at least one disadvantage. Rather than develop new and improved hypoxia agents, or even quibbling about the pros and cons of alternative agents, the nuclear medicine community needs to convince the oncology community that imaging hypoxia is an important procedure that can lead to improved treatment outcome.

引用

页码：169 / +

页数：21

共 134 条

[1]

Adam MF, 1999, HEAD NECK-J SCI SPEC, V21, P146, DOI 10.1002/(SICI)1097-0347(199903)21:2<146::AID-HED8>3.0.CO

[2]

2-U

[3] Mersalyl is a novel inducer of vascular endothelial growth factor gene expression and hypoxia-inducible factor 1 activity [J].